(i) administering an effective amount of <u>human</u> flt3-L to the patient to increase the number of circulating progenitor cells or stem cells prior to collection;

(ii) expanding steel collected [the] progenitor cells or stem cells ex vivo by contacting them with an effective amount of human flt3-L; and

(iii) administering an effective amount of <u>human</u> flt3-L to the patient to facilitate the engraftment of the transplanted progenitor or stem cells in the patient.

Please add the following new claims:

(New) A method for stimulating the proliferation of hematopoeitic stem or progenitor cells in a patient in need thereof, comprising administering a hematopoeitic stem or progenitor cell-stimulating amount of a human flt3-L polypeptide, and optionally, a hematopoeitic stem or progenitor cell-stimulating amount of at least one growth factor selected from the group consisting of CSF-1, GM-CSF, SF, G-CSF, EPO, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, GM-CSF/IL-3 fusion proteins, LIF and FGF.

New) A method for stimulating the proliferation of hematopoeitic stem or progenitor cells in a patient having symptoms of myelodysplastic syndrome, comprising administering a hematopoeitic stem or progenitor cell-stimulating amount of a human flt3-L polypeptide, and optionally, a hematopoeitic stem or progenitor cell-stimulating amount of at least one growth factor selected from the group consisting of CSF-1, GM-CSF, SF, G-CSF, EPO, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, GM-CSF/IL-3 fusion proteins, LIF and FGF.

51. (New) A method for stimulating the proliferation of hematopoeitic stem or progenitor cells in a patient having symptoms of anemia, comprising administering a hematopoeitic stem or progenitor cell-stimulating amount of a human flt3-L polypeptide, and optionally, a hematopoeitic stem or progenitor cell-stimulating amount of at least one growth factor selected from the group consisting of CSF-1, GM-CSF, SF, G-CSF, EPO, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, GM-CSF/IL-3 fusion proteins, LIF and FGF.

New) A method for stimulating the proliferation of hematopoeitic stem or progenitor cells in a patient having symptoms of acquired immune deficiency syndrome, comprising administering a hematopoeitic stem or progenitor cell-stimulating amount of a human flt3-L polypeptide, and optionally, a hematopoeitic stem or progenitor cell-stimulating amount of at least one growth factor selected from

.

Ĉ

2